{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T16:27:35Z","timestamp":1726417655546},"reference-count":48,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Atherosclerosis Supplements"],"published-print":{"date-parts":[[2006,4]]},"DOI":"10.1016\/j.atherosclerosissup.2006.01.007","type":"journal-article","created":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T20:16:15Z","timestamp":1141244175000},"page":"43-49","source":"Crossref","is-referenced-by-count":12,"title":["Diabetes: Assessing the pipeline"],"prefix":"10.1016","volume":"7","author":[{"given":"Harold","family":"Lebovitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosissup.2006.01.007_bib1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJM199807233390404","article-title":"Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction","volume":"339","author":"Haffner","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosissup.2006.01.007_bib2","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1161\/01.CIR.0000111245.75752.C6","article-title":"Definition of metabolic syndrome. Report of the NHLBI\/AHA conference on scientific issues related to definition","volume":"109","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosissup.2006.01.007_bib3","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1210\/en.142.2.521","article-title":"Minireview: the glucagons-like peptides","volume":"142","author":"Drucker","year":"2001","journal-title":"Endocrinology"},{"key":"10.1016\/j.atherosclerosissup.2006.01.007_bib4","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1210\/jcem-63-2-492","article-title":"Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses","volume":"63","author":"Nauck","year":"1986","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.atherosclerosissup.2006.01.007_bib5","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2337\/diabetes.50.3.609","article-title":"Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients","volume":"50","author":"Vilsboll","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.atherosclerosissup.2006.01.007_bib6","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1007\/s001250050613","article-title":"Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7\u201336 amide]) in patients with NIDDM","volume":"39","author":"Nauck","year":"1996","journal-title":"Diabetologia"},{"key":"10.1016\/j.atherosclerosissup.2006.01.007_bib7","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/379069a0","article-title":"A role for glucagon-like peptide-1 in the central regulation of feeding","volume":"379","author":"Turton","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.atherosclerosissup.2006.01.007_bib8","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1210\/en.140.2.778","article-title":"Initiation of increased pancreatic islet growth in young normoglycemic mice (Umea +\/?)","volume":"140","author":"Edvell","year":"1999","journal-title":"Endocrinology"},{"key":"10.1016\/j.atherosclerosissup.2006.01.007_bib9","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.2337\/diabetes.48.12.2270","article-title":"Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats","volume":"48","author":"Xu","year":"1999","journal-title":"Diabetes"},{"key":"10.1016\/j.atherosclerosissup.2006.01.007_bib10","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(02)07952-7","article-title":"Effect of 6-week course of glucagon-like peptide-1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study","volume":"359","author":"Zander","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosissup.2006.01.007_bib11","doi-asserted-by":"crossref","first-page":"380","DOI":"10.2337\/diabetes.52.2.380","article-title":"The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects","volume":"52","author":"Kjems","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.atherosclerosissup.2006.01.007_bib12","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.2337\/diacare.27.11.2628","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes","volume":"27","author":"Buse","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosissup.2006.01.007_bib13","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","article-title":"Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes","volume":"28","author":"DeFronzo","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosissup.2006.01.007_bib14","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2337\/diacare.28.5.1083","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea","volume":"28","author":"Kendall","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosissup.2006.01.007_bib15","series-title":"American Diabetes Association Scientific Sessions","article-title":"Exenatide (exendin-4) reduced A1C and weight over 82 weeks in overweight patients with type 2 diabetes","author":"Blonde","year":"2005"},{"key":"10.1016\/j.atherosclerosissup.2006.01.007_bib16","series-title":"American Diabetes Association Scientific Sessions","article-title":"Comparison of exenatide and insulin glargine in MET and SU-treated patients with type 2 diabetes: exenatide achieved equivalent glycemic control, with weight reduction and less nocturnal hypoglycaemia","author":"Heine","year":"2005"},{"issue":"Suppl 3","key":"10.1016\/j.atherosclerosissup.2006.01.007_bib17","doi-asserted-by":"crossref","first-page":"S233","DOI":"10.2337\/diabetes.53.suppl_3.S233","article-title":"Amylin agonists: a novel approach in the treatment of diabetes","volume":"53","author":"Schmitz","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.atherosclerosissup.2006.01.007_bib18","doi-asserted-by":"crossref","first-page":"784","DOI":"10.2337\/diacare.26.3.784","article-title":"Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial","volume":"26","author":"Hollander","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosissup.2006.01.007_bib19","series-title":"American Diabetes Association Scientific Sessions","article-title":"In an open-label, clinical study pramlintide lowered A1C, body weight and insulin use in patients with type 2 diabetes failing to achieve glycemic targets with insulin therapy","author":"Karl","year":"2005"},{"key":"10.1016\/j.atherosclerosissup.2006.01.007_bib20","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1007\/s00125-005-1732-4","article-title":"Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes","volume":"48","author":"Chapman","year":"2005","journal-title":"Diabetologia"},{"key":"10.1016\/j.atherosclerosissup.2006.01.007_bib21","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0165-6147(00)01805-8","article-title":"Modulation of transmitter release via presynaptic cannabinoid receptors","volume":"22","author":"Schlicker","year":"2001","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.atherosclerosissup.2006.01.007_bib22","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0006-8993(02)03245-6","article-title":"Down-regulation of cannabinoid-1 (CB-1) receptors in specific extrahypothalamic regions of rats with dietary obesity: a role for endogenous cannabinoids in driving appetite for palatable food?","volume":"952","author":"Harrold","year":"2002","journal-title":"Brain Res"},{"issue":"20","key":"10.1016\/j.atherosclerosissup.2006.01.007_bib23","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1056\/NEJMoa044537","article-title":"Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia","volume":"353","author":"Despres","year":"2005","journal-title":"NEJM"},{"key":"10.1016\/j.atherosclerosissup.2006.01.007_bib24","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0140-6736(05)66374-X","article-title":"Effects of the cannbinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study","volume":"365","author":"Van Gaal","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosissup.2006.01.007_bib25","series-title":"American Diabetes Association Scientific Sessions","article-title":"One-year treatment with rimonabant increases plasma adiponectin levels beyond weight loss: the RIO-Lipids trial","author":"Despres","year":"2005"},{"key":"10.1016\/j.atherosclerosissup.2006.01.007_bib26","unstructured":"Scheen AJ. Rimonabant in patients with type 2 diabetes: results from the RIO-Diabetes Trial. American Diabetes Association Late Breaking Clinical Trials. Available at: http:\/\/webcasts.prous.com\/ada2005\/article.asp?CID=YY&CLID=2&AID=85."},{"key":"10.1016\/j.atherosclerosissup.2006.01.007_bib27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0027-5107(99)00231-6","article-title":"Peroxisome proliferator-activated receptors: insight into multiple cellular functions","volume":"448","author":"Escher","year":"2000","journal-title":"Mutat Res"},{"key":"10.1016\/j.atherosclerosissup.2006.01.007_bib28","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/713782132","article-title":"Glitazones: clinical effects and molecular mechanisms","volume":"34","author":"Stumvoll","year":"2002","journal-title":"Ann Med"},{"key":"10.1016\/j.atherosclerosissup.2006.01.007_bib29","series-title":"American Diabetes Association Scientific Sessions","article-title":"Improvement of glycemic control with muraglitazar, a novel dual PPAR \u03b1\/\u03b3 agonist, in combination with metformin in patients with type 2 diabetes: a double-blind, randomized, pioglitazone-controlled study","author":"Rubin","year":"2005"},{"key":"10.1016\/j.atherosclerosissup.2006.01.007_bib30","article-title":"Attainment of A1C goals with muraglitazar, a novel dual PPAR \u03b1\/\u03b3 agonist, in combination with metformin in patients with type 2 diabetes: a double-blind, randomized comparison with pioglitazone plus metformin","author":"Rubin","year":"2005","journal-title":"American Diabetes Association Scientific Sessions"},{"key":"10.1016\/j.atherosclerosissup.2006.01.007_bib31","series-title":"American Diabetes Association Scientific Sessions","article-title":"Glycemic efficacy and safety of muraglitazar, a novel dual PPARalpha\/gamma agonist, plus glyburide in patients with type 2 diabetes failing sulphonylurea monotherapy: a randomized, double-blind, placebo-controlled study","author":"Mohideen","year":"2005"},{"key":"10.1016\/j.atherosclerosissup.2006.01.007_bib32","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.clinthera.2005.08.005","article-title":"Muraglitazar, a dual (alpha\/gamma) PPAR activator: A randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes","volume":"27","author":"Buse","year":"2005","journal-title":"Clin Ther"},{"key":"10.1016\/j.atherosclerosissup.2006.01.007_bib33","unstructured":"Kendall DM, on behalf of the Muraglitazar Study Group. Muraglitazar, a dual \u03b1\/\u03b3 PPAR activator. Effects on glycaemic control and dyslipidemia in patients with type 2 diabetes. Presented at American Diabetes Association 65th Annual Scientific Sessions. Late breaking clinical trials, June 12, 2005."},{"key":"10.1016\/j.atherosclerosissup.2006.01.007_bib34","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1001\/jama.294.20.joc50147","article-title":"Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus","volume":"294","author":"Nissen","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosissup.2006.01.007_bib35","doi-asserted-by":"crossref","first-page":"287480","DOI":"10.2337\/diacare.27.12.2874","article-title":"Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes","volume":"27","author":"Ahren","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosissup.2006.01.007_bib36","article-title":"Tesaglitazar improves glucose and lipid abnormalities in patients with type 2 diabetes","author":"Goldstein","year":"2005","journal-title":"American Diabetes Association Scientific Sessions"},{"key":"10.1016\/j.atherosclerosissup.2006.01.007_bib37","series-title":"European Association for the Study of Diabetes (EASD)","article-title":"Improvements in postprandial lipid handling and glucose tolerance with tesaglitazar in insulin-resistant, nondiabetic patients","author":"Fagerberg","year":"2005"},{"key":"10.1016\/j.atherosclerosissup.2006.01.007_bib38","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1007\/s00125-005-1846-8","article-title":"Tesaglitazar, a novel dual peroxisome proliferator-activated receptor \u03b1\/\u03b3 agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population","volume":"48","author":"Fagerberg","year":"2005","journal-title":"Diabetologia"},{"key":"10.1016\/j.atherosclerosissup.2006.01.007_bib39","series-title":"American Diabetes Association Scientific Sessions","article-title":"Tesaglitazar reduced the prevalence of metabolic syndrome and impaired fasting glucose in an insulin-resistant, non-diabetic population","author":"Schuster","year":"2005"},{"key":"10.1016\/j.atherosclerosissup.2006.01.007_bib40","series-title":"American Diabetes Association Scientific Sessions","article-title":"Tesaglitazar improves apolipoprotein abnormalities in an insulin-resistant, non-diabetic population","author":"Schuster","year":"2005"},{"key":"10.1016\/j.atherosclerosissup.2006.01.007_bib41","series-title":"American Diabetes Association Scientific Sessions","article-title":"Tesaglitazar improves postprandial lipid handling and glucose tolerance in an insulin-resistant, non-diabetic population","author":"Fagerberg","year":"2005"},{"key":"10.1016\/j.atherosclerosissup.2006.01.007_bib42","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2337\/diabetes.47.6.859","article-title":"Perspectives in diabetes: protein kinase C activation and the development of diabetic complications","volume":"47","author":"Koya","year":"1998","journal-title":"Diabetes"},{"key":"10.1016\/j.atherosclerosissup.2006.01.007_bib43","series-title":"American Diabetes Association Scientific Sessions","article-title":"Effect of ruboxistaurin on albuminuria and GFR in persons with type 2 diabetes and nephropathy","author":"Tuttle","year":"2005"},{"key":"10.1016\/j.atherosclerosissup.2006.01.007_bib44","doi-asserted-by":"crossref","unstructured":"The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C-beta inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes 2005;54:2188\u201397.","DOI":"10.2337\/diabetes.54.7.2188"},{"key":"10.1016\/j.atherosclerosissup.2006.01.007_bib45","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.clinthera.2005.08.001","article-title":"Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial","volume":"27","author":"Vinik","year":"2005","journal-title":"Clin Ther"},{"key":"10.1016\/j.atherosclerosissup.2006.01.007_bib46","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.2337\/diacare.26.5.1589","article-title":"New insights on oxidative stress and diabetic complications may lead to a \u201ccausal\u201d antioxidant therapy","volume":"26","author":"Ceriello","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosissup.2006.01.007_bib47","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1172\/JCI21625","article-title":"Increased oxidative stress in obesity and its impact on metabolic syndrome","volume":"114","author":"Furukawa","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.atherosclerosissup.2006.01.007_bib48","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"}],"container-title":["Atherosclerosis Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567568806000080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567568806000080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,17]],"date-time":"2019-04-17T04:24:16Z","timestamp":1555475056000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567568806000080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["S1567568806000080"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2006.01.007","relation":{},"ISSN":["1567-5688"],"issn-type":[{"type":"print","value":"1567-5688"}],"subject":[],"published":{"date-parts":[[2006,4]]}}}